The "head-to-head" comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 1, 2011, Pages 131-139

  Lamot, Lovro ^a,b   Bukovac, Lana T ^b   Vidovic, Mandica ^c   Frleta, Marina ^a   Harjacek, Miroslav ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b SREBRNJAK CHILDREN S HOSPITAL   (Croatia)

^c KBC Zagreb   (Croatia)

Author keywords

Etanercept; Infliximab; Juvenile idiopathic arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CHILL; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HUMAN; HYPERSPLENISM; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MALE; OBSERVATIONAL STUDY; OSTEOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SPLENOMEGALY; THORAX PAIN; TREATMENT DURATION; VOMITING; COMPARATIVE STUDY; HEALTH STATUS; HOSPITALIZATION; JOINT; PATHOPHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; JOINTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955656377     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. RAVELLI A, MARTINI A: Juvenile idiopathic arthritis: Lancet 2007; 369: 767-78
2. RAVELLI A: Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22: 271-5.
3. OEN K: Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002; 16: 347-60.
4. WALLACE CA: Current management of juvenile idiopathic arthritis: Best Pract Res Clin Rheumatol 2006; 20: 279-300
5. ILOWITE NT: Current treatment of juvenile rheumatoid arthritis: Pediatrics 2002; 109: 109-15
6. HASHKES PJ, LAXER RM: Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 1671-84.
7. OSTLIE IL, AASLAND A, JOHANSSON I, FLATO B, MOLLER A: A longitudinal follow-up study of physical and psychosocial health in young adults with chronic childhood arthritis. Clin Exp Rheumatol 2009; 27: 1039-46.
8. MAGNI-MANZONI S, ROSSI F, PISTORIO A et al.: Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum 2003; 48: 3509-17.
9. VAN ROSSUM MA, BOERS M, ZWINDERMAN AH et al.: Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum 2005; 52: 2865-72.
10. ROSSI F, DI DIA F, GALIPO O et al.: Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2006; 55: 717-23.
11. MURRAY KJ, LOVELL DJ: Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16: 361-78.
12. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
13. HORNEFF G, SCHMELING H, BIEDERMANN T et al.: The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
14. LOVELL DJ, REIFF A, JONES OY et al.: Longterm safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-94.
15. HAINES KA: Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis 2007; 65: 205-11.
16. RUPERTO N, LOVELL DJ, CUTTICA R et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56: 3096-106.
17. LOVELL DJ, RUPERTO N, GOODMAN S et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
18. HENRICKSON M, REIFF A: Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31: 2055-61.
19. TSE SM, BURGOS-VARGAS R, LAXER RM: Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52: 2103-8.
20. HORNEFF G, BURGOS-VARGAS R: Juvenile idiopathic arthritis. Subgroup characteristics and comparisons between rheumatoid arthritis-like subgroups and ankylosing spondylitis-like subgroups. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S131-8.
21. DEKKER L, ARMBRUST W, RADEMAKER CM, PRAKKEN B, KUIS W, WULFFRAAT NM: Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22: 252-8.
22. ARMBRUST W, KAMPHUIS SS, WOLFS TW et al.: Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004; 43: 527-9.
23. LAHDENNE P, VAHASALO P, HONKANEN V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245-7.
24. HARJACEK M, RUPERTO N, OSTOJIC J, BUKOVAC LT: The Croatian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19 (Suppl. 23): S40-4.
25. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
26. GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
27. WALLACE CA, RUPERTO N, GIANNINI E: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
28. RAVELLI A, MARTINI A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S105-10.
29. VAN RIEL PL, SCHUMACHER HR JR: How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol 2001; 15: 67-76
30. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
31. CONSOLARO A, RUPERTO N, BAZSO A et al.: Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
32. CARTER JD, LADHANI A, RICCA LR, VALERIANO J, VASEY FB: A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-41.
33. BRAUN-MOSCOVICI Y, MARKOVITS D, ROZIN A, TOLEDANO K, NAHIR AM, BALBIRGURMAN A: Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008; 10: 277-81.
34. HAYWARD K, WALLACE CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11: 216.
35. PASCOLI L NN, WRAY M, MCCARRON M, MCALLISTER C, ROONEY ME: Knee joint in JIA: a prospective study-ultrasound is more sensitive than both clinical examination and MRI in detecting disease activity. Arthritis Rheum 2009; 60 (Suppl.) (Abstract).
36. MAGNI-MANZONI S, EPIS O, RAVELLI A et al.: Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 1497-504.
37. NAREDO E, BONILLA G, GAMERO F, USON J, CARMONA L, LAFFON A: Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005; 64: 375-81.
38. SOKKA T, PINCUS T: Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 713-22, v-vi.
39. NAREDO E, RODRIGUEZ M, CAMPOS C et al.: Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59: 515-22.
40. RINGOLD S, CHON Y, SINGER NG: Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 3776-83.
41. ILOWITE NT: Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008; 20: 613-8.
42. LOVELL DJ, REIFF A, ILOWITE NT et al.: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-504.
43. Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). In: FDA UD Food and Drug Administration (online).